FibroGen Completes Asset Acquisition
Ticker: KYNB · Form: 8-K · Filed: Sep 5, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $220 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, disposition, assets
TL;DR
FibroGen just closed a big asset deal. Big moves ahead.
AI Summary
FibroGen, Inc. announced the completion of its acquisition of assets on August 29, 2025. The company, incorporated in Delaware, filed its 8-K report on September 5, 2025, detailing this significant corporate event. The filing includes financial statements and exhibits related to the asset disposition.
Why It Matters
This filing signifies a major strategic move for FibroGen, Inc., potentially impacting its future growth, product pipeline, and market position.
Risk Assessment
Risk Level: medium — Acquisitions and dispositions of assets carry inherent risks related to integration, valuation, and future performance.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
- September 5, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices City and State
- 415-978-1200 (phone_number) — Registrant's Telephone Number
FAQ
What specific assets were acquired or disposed of by FibroGen, Inc.?
The filing indicates the completion of an acquisition or disposition of assets, but the specific details of the assets involved are not provided in this excerpt.
What is the financial impact of this asset transaction on FibroGen, Inc.?
The filing states that financial statements and exhibits are included, suggesting financial details are available, but they are not summarized in this initial report.
When did the asset acquisition or disposition officially close?
The earliest event reported, which is the completion of the acquisition or disposition of assets, occurred on August 29, 2025.
What is the primary business of FibroGen, Inc.?
FibroGen, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Where is FibroGen, Inc. headquartered?
FibroGen, Inc.'s principal executive offices are located at 350 Bay Street, Suite 100 #6009, San Francisco, California.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-09-05 17:04:36
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
- $220 m — Ltd. to AstraZeneca, for approximately $220 million, as previously disclosed on a Cur
Filing Documents
- fgen-20250829.htm (8-K) — 47KB
- fgen-ex99_1.htm (EX-99.1) — 348KB
- 0000921299-25-000007.txt ( ) — 513KB
- fgen-20250829.xsd (EX-101.SCH) — 24KB
- fgen-20250829_htm.xml (XML) — 5KB
01 Completion of Acquisition or Disposition of Assets
Item 2.01 Completion of Acquisition or Disposition of Assets. This Current Report on Form 8-K is being filed in connection with the completion on August 29, 2025, or the closing (the "Closing"), of the transaction contemplated by the Share Purchase Agreement, dated February 20, 2025, and entered into with AstraZeneca Treasury Limited ("AstraZeneca") pursuant to which we and our indirect subsidiary FibroGen China Anemia Holdings, Ltd. sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 million, as previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on September 2, 2025.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (b) Pro Forma Financial Information. The Company's unaudited pro forma condensed consolidated balance sheet as of June 30, 2025 and unaudited pro forma condensed consolidated statements of operations for the year ended December 31, 2024, are filed as Exhibit 99.1 hereto and are incorporated into this Item 9.01(b) by reference. (d) Exhibits Exhibit No. Description 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FibroGen, Inc. Date: September 5, 2025 By: /s/ John Alden John Alden General Counsel